Myriad Genetics, Inc. (MYGN) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Myriad Genetics, Inc. (MYGN)

An SI Board Since August 1996

Posts	SubjectMarks	Bans	Symbol
2355	65	0	MYGN

Emcee: s myers	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
630	archneur.ama-assn.org <i>In the case of -secretase, the situation is more	scaram(o)uche	-	2/23/2005
629	According to pdg.cnb.uam.es DEP1 is a synonym for gene PTPRJ - Protein-tyr	tnsaf	-	2/21/2005
628	DEP1 with Abbott....... I have zero clue re. the identity of DEP1, not a clue.	scaram(o)uche	-	2/19/2005
627	sitting here collared, at about the same price where the block changed hands aft	scaram(o)uche	-	2/17/2005
626	Biochem Pharmacol. 2005 Mar 1;69(5):831-9. Epub 2005 Jan 13. Induction of apop	scaram(o)uche	-	2/17/2005
625	SCHEDULE 13G Amendment No. 1 Name of Issuer: Myriad Genetics, Inc Title of Class	scaram(o)uche	-	2/15/2005
624	down from 2,198,500 last proxy. (eom)	scaram(o)uche	-	2/14/2005
623	1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE	scaram(o)uche	-	2/14/2005
622	up from 3,397,000, last proxy.	scaram(o)uche	-	2/11/2005
621	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	scaram(o)uche	-	2/11/2005
620	Br J Pharmacol. 2005 Feb 07; [Epub ahead of print] The role of substance P in	scaram(o)uche	-	2/9/2005
619	>> preclinical experiments ONGOING to assess the potential of MPC-2130 in	scaram(o)uche	-	2/9/2005
618	additional comments (thanks for the transcript, Jim!)..... 1. enrollment in th	scaram(o)uche	-	2/9/2005
617	hey, thanks Ashley! Rick	scaram(o)uche	-	2/8/2005
616	Just listened to the conference call. Interesting format. Each quarter they pi	A.J. Mullen	-	2/8/2005
615	from today's 10Q..... <i>We also have a number of drug candidates in	scaram(o)uche	-	2/8/2005
614	Myriad Genetics Reports Results for Second Quarter of Fiscal 2005 Tuesday Februa	scaram(o)uche	-	2/8/2005
613	I pass on posting most substance P/NK-1 receptor stuff. Thought this one might	scaram(o)uche	-	2/4/2005
612	Dr. Green's last three publications...... Genet Med. 2005 Jan;7(1):48-53.	scaram(o)uche	-	2/3/2005
611	factually wanting, that Business Week article is quite irresponsible..... a b	scaram(o)uche	-	2/3/2005
610	businessweek.com (link from BobRussak at yahoo) LAB REPORT By Cathy Arnst A	scaram(o)uche	-	2/3/2005
609	pipeline chart updated again..... myriad.com I'm curious as heck about 450	scaram(o)uche	-	2/2/2005
608	Ann N Y Acad Sci. 2004 Dec;1035:68-84. NSAID and Antioxidant Prevention of Alz	scaram(o)uche	-	2/2/2005
607	CUSIP No. 62855J104 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S.	scaram(o)uche	-	2/1/2005
606	apples to apples, nice find. thanks!	scaram(o)uche	-	2/1/2005

Go to reply# or date (mm/dd/yy):